Hypothyroidism has been associated with significantly elevated risk for hepatocellular carcinoma (HCC), although the precise underlying mechanisms remain unknown at present. Thyroid hormone (T 3 ) and its receptor (TR) are involved in metabolism and growth. Endoglin is a T 3 /TR candidate target gene identified from our previous studies. Here, we demonstrated that T 3 positively regulates endoglin mRNA and protein levels, both in vitro and in vivo. The thyroid hormone response elements of endoglin were identified at positions À 2114/ À 2004 and À 2032/ À 1973 of the promoter region using the electrophoretic mobility shift assay and chromatin immunoprecipitation assay. Endoglin was downregulated in the subgroups of HCC patients and significantly associated with histology grade (negative association, P ¼ 0.001), and this expression level was significantly associated with TRa1 in these HCC patients. Our results clearly indicate that p21 is involved in T 3 -mediated suppression of cell proliferation. Knock down of endoglin expression in HCC cells facilitated p21 polyubiquitination and promoted cell proliferation in the presence of T 3 . The data collectively suggest that T 3 /TR signaling suppresses cell proliferation by upregulating endoglin, in turn, affecting p21 stability. The results indicate that endoglin has a suppressor role to inhibit cell proliferation in HCC cell lines.
INTRODUCTION
The thyroid hormone (3, 3 0 , 5-triiodo-L-thyronine; T 3 ) regulates cell homeostasis, growth, development and differentiation, 1 and its effects are mediated by thyroid hormone receptors (TRs). Human TRs are encoded by TRa1 and TRb1 genes located on human chromosomes 17 and 3, respectively. 2 TRs function in a liganddependent manner via binding to thyroid hormone response elements (TRE) of target gene promoter regions. Several types of TREs have been identified to date, specifically, direct repeat (DR4), inverted palindrome (F2) and palindrome (pal). 3 TRs interact with each other to form homodimers or with retinoid X receptor to form heterodimers that regulate gene expression. Hormone binding induces TR conformational changes, causing corepressor release and coactivator binding that lead to chromatin modifications and transcriptional activation. 4 Liver is one of the target organs of thyroid hormone. Normal hepatocytes express both TRa1 and TRb1. 5 A number of studies to date have shown aberrant expression or mutation of TRs in pituitary tumors, 6 hepatocellular carcinoma (HCC) 7 and thyroid cancer. 8 Recently, hypothyroidism in women was reported as a high risk factor for HCC. 9 These findings indicate that the thyroid hormone and its receptor have suppressor roles in tumor formation. However, the associated mechanisms are yet to be established.
Previous microarray analyses led to the identification of endoglin as a T 3 /TR candidate target gene. Endoglin, a transforming growth factor (TGF) b type III coreceptor, belongs to a component of the TGFb receptor complex that binds TGFb1, TGFb3, activin-A and bone morphogenetic protein-2 in the presence of type I and II TGFb receptors 10 and modulates TGFb1-dependent responses. 11 The gene encodes a disulfidelinked homodimeric cell membrane glycoprotein that is highly expressed in endothelial cells (ECs) . 12 Earlier studies have demonstrated that overexpression of endoglin in human prostate cancer and breast cancer suppresses metastasis. 13, 14 Furthermore, disruption of membrane endoglin has emerged as a crucial event to promote mouse skin carcinogenesis. 15 The data collectively suggest that endoglin functions as a tumor-suppressor gene. P21 is another important tumor-suppressor gene regulated at two levels. At the transcriptional level, p21 is regulated in a p53-dependent or -independent manner, 16, 17 while at the translational level, p21 is a short-lived protein degraded by the proteasome in a ubiquitination-dependent or -independent manner. 18, 19 Overexpression of p21 causes cancer cell-cycle arrest, apoptosis and senescence. 20, 21 So far, the association between the thyroid hormone and endoglin, and their functions in HCC cell lines are yet to be clarified.
In the current study, we demonstrated that T 3 upregulates endoglin expression in HepG2-TR-expressing cells in vivo as well as in vitro. Two TREs were further identified on the endoglin promoter region. Moreover, p21 protein stability was increased in association with endoglin activity in cells treated with T 3 , leading to suppression of cell proliferation.
RESULTS
L-endoglin mRNA is upregulated by T 3 /TR In previous studies, two endoglin isoforms were identified, specifically, L-form (L-ENG) and S-form (S-ENG), differing in terms of cytoplasmic domain composition. L-endoglin contains 47 amino acids in the cytoplasmic domain, whereas S-endoglin only has 14 amino acids. The difference between those two transcripts is an intronic 135 bp insert that is retained in S-endoglin. 22, 23 We designed specific primers to distinguish the isoform expressed in HCC cell lines (Figure 1a ). The reverse transcriptase (RT)-PCR products for S-ENG and L-ENG were 701 and 565 bp, respectively. The L-ENG was found highly expressed in Hep3B, J7 and SK-Hep1 cells, but did not express in HepG2, Huh7 and Mahlavu cells. Notably, S-ENG was not detectable in all the HCC cell lines using RT-PCR (Figure 1b) . To determine whether L-ENG is regulated by T 3 /TR, TRa1-and TRb1-overexpressing HepG2 cell lines were established, along with HepG2-neo as a negative control (Figure 1c) . The endoglin mRNA level was increased by 3.2-95-fold following incubation of HepG2-TR cells with T 3 in a time-and dose-dependent manner (Figure 1d ). Endoglin mRNA was marginally induced in HepG2-neo cells expressing barely detectable levels of TR. Endoglin mRNA expression was determined in J7 cells expressing low levels of endogenous TR 24 treated with/without 0-100 nM T 3 for 24-72 h using quantitative RT-PCR (qRT-PCR). The data showed that endoglin mRNA is upregulated (2.2-5-fold) in J7 cells treated with T 3 (Figure 1d ). T 3 /TR upregulates endoglin protein expression in HepG2-TR cells Endoglin has been identified as a glycoprotein. 25 The glycolendoglin molecular weight size shifted from 95 kDa to 72 kDa after treatment with glycosidase F to remove the glycol group (Supplementary Figure S1) . Our data indicate that endoglin was induced by T 3 about 2-22-fold and 3.5-11-fold in HepG2-TRa1 ( Figure 2a ) and HepG2-TRb1 (Figure 2b ) cells, respectively. Furthermore, T 3 increased the endoglin protein level slightly (1.2-1.8-fold) in J7 cells (Figure 2c ). Endoglin protein expression was not increased in HepG2-neo cells treated with T 3 (Figure 2d ).
T 3 -dependent activation of the endoglin promoter via TR The promoter activity assay was performed to determine whether endoglin is regulated by T 3 at the transcriptional level. The endoglin 5 0 -flanking regions at positions À 2683/ þ 351 (fragment I), À 850/ þ 351 (fragment II) and À 400/ þ 351 (fragment III) were cloned into pGL3-basic vector (translation start site, þ 1). The pGL3-reporter plasmids were co-transfected with pcDNA-TRa1 into CV-1 cells, followed by exposure to T 3 . The luciferase activity of fragment I was increased 2.7-fold in CV-1 cells after T 3 treatment, while activities of the other fragments (II and III) were not upregulated by T 3 /TR (Figure 3a) . The data indicate that TRE is located within the À 2683/ À 850 region. A bioinformatics tool was used to predict putative TREs in the endoglin promoter region (DR4 and F2), presented in Figure 3a . Various deletion fragments (IV-XIII) were generated using PCR and inserted upstream of minimal thymidine kinase promoter vector (pA3TK plasmid). Luciferase activity was increased by about 2. The electrophoretic mobility shift assay (EMSA) was used to further confirm whether TR binds directly to the two potential TREs on the promoter fragment of endoglin. The a-P 32 -labeled Upregulation of endoglin by T 3 in thyroidectomized rats and downregulation in human HCC To establish whether endoglin is regulated by T 3 /TR in vivo, experiments were performed on hyper-(Tx þ T 3 ), hypo-(Tx) and euthyroid (sham) rats. Total RNAs or proteins were extracted from livers and endoglin expression detected using qRT-PCR and western blot, respectively. Endoglin mRNA was induced about (Figure 5a ). The proliferation rate was measured for 1, 3 and 5 days. The proliferative properties of control and knockdown cells not subjected to T 3 treatment were comparable. However, cells depleted of endoglin displayed a higher proliferation rate than the control cell line in the presence of T 3 (Figure 5b) . A similar effect was observed in the colony-formation assay (data not shown). The results indicate that endoglin is involved in T 3 -mediated suppression of cell proliferation. Furthermore, the cell cycle in HepG2-TRa1-sh-luc cells treated with T 3 was dramatically arrested at the G 0 /G1 phase (66.35±4.37% vs 41.05±1.68%). However, knock down of endoglin ameliorated the T 3 -induced cell-cycle progression arrest at the G 0 /G1 phase (66.35 ± 4.37% vs 52.58 ± 1.07%) (Figure 5c) .
Conversely, the effects of endoglin overexpression in HCC cells were analyzed (Figure 6a ). Endoglin-overexpressing clones were generated in Huh7 cells, which expressed lowest compared with other HCC cells by western blot (data not shown). Interestingly, overexpression of TRa1 in Huh7 cells did not induce endoglin expression in the presence of T 3 . We proposed that endoglin regulation was controlled by epigenetic modifications. To investigate this possibility, endoglin mRNA was measured by qRT-PCR following 5 0 -azacytidine treatment. As shown in Figure 6b , endoglin was significantly induced by treating with 5 0 -azacytidine. The cell proliferation rate was reduced in cells expressing both endoglin and TRa1 but not in those expressing TRa1 alone (Figure 6c ). Our results further confirm a suppressor role of endoglin to inhibit proliferation in HCC cell lines.
Knock down of endoglin blocks p21-mediated T 3 reduction of cell proliferation To investigate the effects of endoglin knock down, cell-cyclerelated proteins were examined. Expression of p21 was induced in 0 -azacytidine, and cells harvested after 6 days of treatment. RNA was extracted, and endoglin mRNA expression detected using qRT-PCR. Data were normalized to RiboL35A and presented as means±s.d. of three independent experiments. (c) Ad-TRa-infected cells overexpressing ENG or neo control were incubated with or without T 3 , and cell proliferation detected with the MTT assay. Data were obtained from three independent experiments performed in triplicate. (d) Expression levels of p21 and p53 proteins were determined in HepG2-TRa1-sh-luc and HepG2-TRa1-shENG cells using western blot. (e) P21 mRNA expression was measured in HepG2-TRa1-sh-luc and HepG2-TRa1-shENG cells with qRT-PCR. Data were normalized to RiboL35A and presented as mean values ± s.d. of three independent experiments. (f) HepG2-TRa1-sh-luc and HepG2-TRa1-shENG cells were initially incubated with or without T 3 for 20 h and treated with MG132 (10 mM) for an additional 4 h. Other inhibitors, SB431542 (10 mM), LiCl (100 mM), LY294002 (20 mM) and Lactacystin (10 nM), were co-treated with T 3 for 24 h. Following treatment, cells were harvested, and p21 protein expression assessed using western blot. (g) The p21 protein turnover rate was determined using cycloheximide (CHX). HepG2-TRa1-sh-luc and HepG2-TRa1-shENG cells were treated with T 3 (10 nM) for 24 h, followed by incubation with CHX (10 mg/ml). Cell lysates were collected at the indicated times, and p21 expression detected via western blot. The intensity of p21 was quantified and normalized to GAPDH, as shown on the bottom panel. (h) HepG2-TRa1-sh-luc and HepG2-TRa1-shENG cells were incubated with/without T 3 . After 24 h treatment, lysates were extracted. Endogenous p21 was immunoprecipitated with anti-p21 antibody and detected ubiquitinated p21 by anti-ubiquitin antibody. Immunoprecipitated p21 was immunoblotted as input control. *indicates non-specific band.
the presence of T 3 but blocked in shENG cells (Figure 6d, lane 2 vs  lane 4) . Additionally, p21 protein expression was more stable in cell lines expressing both TRa1 and endoglin, compared with those with TRa1 overexpression only (Figure 6a, lane 2 vs lane 4) . This finding suggests that p21 protein is upregulated by T 3 /TR through endoglin. To investigate whether p21 is involved in T 3 /TRmediated reduction of cell proliferation, p21 knock down was achieved in HepG2-TRa1 cells. Knockdown efficiency was detected via western blot analysis (Supplementary Figure S2a) . The proliferation rate in p21 knockdown cells was similar, compared with control cells, in T 3 -depleted conditions. However, the proliferative property of HepG2-TRa1-sh-p21 cells was partially increased, relative to that of HepG2-TRa1-sh-luc cells, following T 3 treatment (Supplementary Figure S2b) . Moreover, knock down of p21 ameliorated T 3 -induced cell-cycle arrest at the G 0 /G1 phase (44.82 ± 2.07%), compared with control cells (62.99 ± 2.80%) (Supplementary Figure S2c) . These characteristics were similar to those of the endoglin knock down (HepG2-TRa1-shENG) phenotype (Figures 5b and c) . Our results clearly indicate that p21 is involved in T 3 -mediated suppression of cell proliferation. Earlier studies have identified p21 as a tumor-suppressor gene induced by p53. 16 However, in our experiments, p53 was slightly downregulated by T 3 /TR in both the control and endoglin knockdown cell lines (Figure 6d ). The data suggest that p21 is upregulated by T 3 /TR independently of p53. Furthermore, p21 mRNA was upregulated by T 3 /TR in both HepG2-TRa1-sh-luc and HepG2-TRa1-shENG cell lines (Figure 6e ), indicating that p21 expression is regulated by endoglin at the translational but not at the transcriptional level. Expression of p21 protein has been shown to be regulated by TGFb1, glycogen synthase kinase 3 alpha/beta and the protein kinase B (Akt) pathway. [26] [27] [28] The mechanisms underlying regulation of p21 were further examined in the current study. Interestingly, expression of p21 was only stabilized by the proteasome inhibitors, MG132 and lactacystin, in endoglin knockdown cells (Figure 6f ), implying that endoglin controls p21 protein stability directly through proteasome but not through other signaling pathway. Moreover, the p21 turnover rate was rapid in endoglin knockdown cells, compared with the control (sh-luc), following T 3 treatment in a cycloheximide chase experiment (Figure 6g ). To further confirm whether T 3 controls p21 stability through ubiquitination, the p21 ubiquitination assay was performed. Knock down of endoglin in T 3 conditions facilitated p21 polyubiquitination, compared with control ( Figure 6h, lane 2 vs 4) . The data collectively suggest that T 3 /TR signaling suppresses cell proliferation by upregulating endoglin, in turn, affecting p21 stability. To date, the potential function of endoglin in cancer progression has been a controversial issue. Oxmann et al. 29 reported that overexpression of endoglin in a breast cancer cell line promotes invasion ability through matrix metalloproteinase (MMP)-1 and MMP-19 upregulation. The group additionally showed that endoglin-overexpressing cells preferentially produce invadopodia extending from the cell surface. Conversely, Bergan and colleagues 13, 30 demonstrated that endoglin overexpression in prostate cancer cells increases cell attachment and decreases migration and invasion ability. Moreover, knock down of Smad1 or ALK2 (type I activin receptor-like kinases) abrogated the effects of endoglin. Perez-Gomez et al. 15 suggested that forced expression of L-endoglin in spindle carcinoma cells (high anaplastic tumors) disrupts smad2/3 signaling and inhibits tumor formation.
Previously, Yu et al. 31 had demonstrated that endoglin expression is restricted to hepatic sinus ECs of normal liver tissue. Experiments performed by Benetti et al. 32 on isolated ECs from adjacent non-neoplastic tissue and HCC disclosed higher expression of endoglin in HCC-derived ECs and greater migration ability than non-neoplastic tissue-EC. However, endoglin (CD105) is not an appropriate target for angiogenesis therapy, as the protein is expressed not only in neovessels of tumors but also in hepatic sinus ECs in non-tumor regions. 31 Moreover, limited evidence confirming endoglin expression in normal hepatocytes and tumor cells in HCC has been obtained to date. Therefore, the functional role of endoglin in HCC cells is currently unclear. IHC staining experiments by our group showed that endoglin is expressed in both normal and tumor cells and not just in ECs. Similar results have been observed in breast cancer. 14 We proposed that endoglin has a specific function in HCC cells. Surprisingly, knock down of endoglin promoted cell proliferation under conditions of T 3 treatment in HCC cells. The results indicate that endoglin has a suppressor role to inhibit cell proliferation in HCC cell lines.
Yen et al. 33 reported that T 3 induces the expression of cell-cyclerelated proteins, such as cyclin E1, cdk2, pRb and p21, leading to reduced cell proliferation. The group further showed that TGFb1 is upregulated by T 3 /TR. Interestingly, treatment with a TGFb1-neutralizing antibody blocked T 3 /TR-regulated cyclin E1, cdk2 and pRb but not p21. The results suggest that p21 is not regulated by TGFb1 in the HepG2-TRa1 cell line, consistent with our findings. Upon treatment of HepG2-TRa1-shENG cells with T 3 and SB431542 (a TGFb signaling inhibitor), p21 protein expression was not restored. Cyclin E1, cdk2 and pRb expression were not significantly different between HepG2-TRa1-sh-luc and HepG2-TRa1-shENG cells (data not shown). At the transcriptional level, p21 was upregulated by T 3 /TR in a p53-independent manner in HepG2-TRa1 cells, consistent with the earlier report of Aliouat-Denis et al. 17 The results support the transcriptional activation of p21 in p53-defective SK-BR-3 and HaCaT cells. To further determine whether p21 is directly or indirectly regulated by T 3 /TR, p21 mRNA expression was examined in cells treated with T 3 and cycloheximide. Our data suggest that p21 mRNA is directly regulated by T 3 /TR (Supplementary Figure S3) . To further confirm whether p21 regulation was p53 independent, Hep3B, a p53-deficient cell line, 34 overexpressing TR (Hep3B-TRa1) was generated. P21 protein expression was measured in the absence or presence of T 3 . Our data indicate that p21 is upregulated by T 3 /TR in p53-null cells. Additionally, endoglin was upregulated and the proliferation rate reduced by T 3 in Hep3B-TRa1 cells (Supplementary Figures S4a, S4b) . Accordingly, we propose that T 3 simultaneously enhances endoglin and p21 expression and contributes to the suppression of proliferation in p53-null Hep3B cells.
Endoglin was not upregulated by T 3 in Huh7-TRa1 cells. Earlier, Henry et al.
14 reported that endoglin is silenced by epigenetic regulation. This finding was confirmed in the current study, as endoglin was induced after 5 0 -azacytidine treatment in Huh7 cells. Consistent with these findings, epigenetic regulation of endoglin in a breast cancer cell line has been reported.
The role of TRs in cancer is a contentious issue. Recently, overexpression of TRa1 and Wnt pathway activation were shown to promote colorectal cancer formation. 35 The group demonstrated that TRa1 promotes tumorigenesis in APC þ /1638N mice with a Wnt-activated genetic background. However, TRa1 overexpression alone was unable to trigger tumor formation. By contrast, transgenic mice (TRb pv/pv ) harboring a PV mutant displayed thyroid hormone resistance and spontaneously developed thyroid cancer. 36 Martinez-Iglesias et al. 37 provided evidence supporting the activity of TRb1 as a tumor suppressor in HCC and breast cancer. Overexpression of TRb1 in SK-Hep1 and MDA-MB-468 (a breast cancer cell line) suppressed tumor metastasis in vitro and in vivo, 37 further validating a suppressor role of TR. An earlier study by our group demonstrated that the PTTG1 oncogene is downregulated by T 3 /TRs. Knock down of PTTG1 expression suppressed HepG2-TRa1 cell growth. 24 Similarly, DKK4 was upregulated by T 3 /TR. Overexpression of DKK4 in J7 cells suppressed tumor formation and metastasis in vivo. 38 In view of these findings, we proposed that the PTTG1 oncogene and tumor-suppressor gene, DKK4 and endoglin, are down-or upregulated by T 3 /TR, respectively, thus suppressing cell proliferation in HCC.
In conclusion, endoglin expression in HCC samples is highly associated with that of TRa1. Endoglin knock down can partially rescue T 3 /TR inhibition of cell proliferation mediated through increased p21 stability. Furthermore, p21 is regulated by endoglin at the translational level. Based on the study findings, we propose that endoglin protects p21 from proteasome degradation, in turn, suppressing cell proliferation.
MATERIALS AND METHODS

Cell culture conditions and treatments
HepG2, Huh7, Hep3B, J7, Mahlavu and SK-Hep1 cell lines were cultured in DMEM (Dulbecco's modified Eagle's medium) containing 10% (v/v) fetal bovine serum. Stable cell lines, including HepG2-TRa1, HepG2-TRb1 and HepG2-neo, were cultured in DMEM containing 10% (v/v) fetal bovine serum with G418. T 3 was obtained from Sigma-Aldrich, St Louis, MO, USA. Serum was depleted of T 3 using AG 1-X8 resin (Bio-Rad, Hercules, CA, USA). Cells were cultured at 37 1C in a humidified atmosphere of 95% air and 5% CO 2 .
Semi-quantitative and qRT-PCR Total RNA was extracted from cells using the TRIzol reagent kit (Life Technology Inc., Carlsbad, CA, USA). RNA was converted to cDNA using reverse transcriptase (Life Technology). An endoglin isoform-specific primer pair was designed for RT-PCR. Endoglin amplification was performed under the following conditions: 95 1C denaturation for 5 min, followed by 28 cycles of denaturation at 95 1C for 30 s, 58 1C annealing for 30 s and 72 1C elongation for 1 min. Real-time quantitative PCR was conducted in a 15-ml reaction mixture containing forward and reverse primers and 1X SYBR Green mix (Applied Biosystems, Carlsbad, CA, USA). The sequences of primer in RT-PCR and qRT-PCR are listed in Supplementary Table S1 .
Immunoblotting analysis
The detailed immunoblotting analysis has been described previously. 39 Antibodies against endoglin (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), p53 (Santa Cruz), p21 (Thermo Fisher Scientific Inc., Kalamazoo, MI, USA), GAPDH (Merck Millipore, Billerica, MA, USA), b-actin (Merck Millipore) and C4 antibody (a gift from S-Y Cheng, National Cancer Institute) against TRa1 and TRb1 were used in this study. Band intensities were calculated using Image Gauge software (Fuji Film, Tokyo, Japan).
IHC staining
The detailed IHC staining protocol has been described previously. 40 Briefly, primary endoglin antibody (Sigma-Aldrich) was used at a 1:100 dilution, along with the horseradish peroxidase-conjugated anti-rabbit secondary antibody (Santa Cruz). Signals were detected using the EnVision kit (DAKO, Carpinteria, CA, USA). Endoglin-positive staining was visualized as a brown color.
Cloning of the endoglin promoter and promoter activity analysis Fragments of the endoglin promoter were amplified via PCR according to the published nucleotide sequence and cloned into pGL3-basic or pA3TK vector. To measure the effects of T 3 on transcriptional activity of the endoglin promoter, CV-1 cells were seeded (3 Â 10 4 cells/well, in a 24-well plate) and cotransfected with reporter plasmid and TRa1-expressing plasmid using TurboFect (Fermentas, Glen Burnie, MD, USA). Cells were additionally transfected with the b-galactosidase expression vector, pSVb (Clontech Laboratories, Inc., CA, USA), as a transfection control as described previously. 41 Luciferase activity was normalized to b-galactosidase activity.
All values was normalized with those of empty vector and compared with those obtained in the absence of T 3 .
EMSA
Two endoglin promoter fragments (positions À 2114/ À 2004 and À 2032/ À 1973) were amplified and labeled with a-32 P dCTP as a probe. Another endoglin promoter fragment ( À 2213/ À 2076) served as a negative control. For the EMSA experiment, equal amounts of TRa1, TRb1 and RXRa proteins generated via in vitro translation (Promega Corp., Madison, WI, USA) were incubated with the a-32 P-labeled endoglin promoter fragments, as described previously. 42 The C4 antibody generated against TRa and TRb was used to observe supershifts in the complexes. MOPC21, a mouse monoclonal antibody, was used as the negative control (ICN Biomedicals, Aurora, OH, USA). Primers for the EMSA experiments are listed in Supplementary Table S2 .
ChIP assay
The ChIP assay was performed to detect the interactions between TR and TREs on the endoglin promoter regions, as described in a previous report. 41 The following primers are listed in Supplementary Table S2 .
Thyroidectomy and human HCC specimens
Hypo-, hyper-and euthyroid rats were generated according to a previous report. 43 All animal experiments in this study were performed according to the NIH and Chang Gang Institutional Animal Care guidelines. Additionally, 80 HCC samples obtained between 2000 and 2003 were selected for study. All HCC tissue samples with paired adjacent normal liver tissues were acquired during surgical resection from the Chang Gung Memorial Hospital medical research center for western blot analysis. The protocol was approved by the Medical Ethics and Human Clinical Trial Committee at Chang-Gung Memorial Hospital.
Establishment of endoglin-expressing stable cell lines
The pCMV5-endoglin vector, a gift from Dr Gallione (Duke University), was subcloned into pcDNA3.0 vector. Transfection of the endoglin expression vector in Huh7 cells was performed using TurboFect (Fermentas), and stable clones selected in medium containing G418 for 2 weeks. Huh7-ENG was used as the endoglin-overexpressing cell line and Huh7-neo as the control cell line. The clone (TRCN000084138) of shRNA targeting endoglin 3 0 untranslated region was purchased from the National RNA Interference Core Facility (Institute of Molecular Biology, Academia Sinica, Taipei, Taiwan). The shENG or sh-luc plasmids and virus package plasmids (pCMV À DR8.91 and pMD.G) were co-transfected into 293FT, and the virus harvested after 72 h of transfection. HepG2-TRa1 and SK-Hep1-TRa1 cells were infected with shENG and sh-luc virus, and stable infectants selected in medium containing puromycin.
Recombinant adenovirus generation and infection
TRa1 cDNA was cloned into the pAd-track CMV vector, as described previously. 44 The plasmid was subsequently linearized by PmeI restriction enzymes and cotransformed with pAdEasy in BJ5183 competent cells. The pAdEasy-TRa1 construct was linearized by PacI restriction enzyme, transfected into 293 cells using TurboFect (Fermentas) and the virus harvested.
Cell proliferation assay Cells (4 Â 10 3 /well) were grown on a 48-well plate. At different time-points, cell growth rates were determined using 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT; Promega). Absorbance and background were measured at 570 and 650 nm, respectively, with the Titertek Multiscan Plus MK1-ELISA reader (Labsystems and Life Science International, Haver Hill, UK). Results are presented as fold change of each control value.
Detection of cell-cycle progression with propidium iodide staining Cells were starved in serum-free medium for 24 h, followed by incubation in medium with or without T 3 . After 24 h of treatment, cells were harvested with trypsin and washed twice with cold phosphate-buffered saline. Subsequently, cells were fixed with 70% ethanol for 1 h at À 20 1C and incubated in 0.5% Triton X-100/phosphate-buffered saline containing
